SAN DIEGO, Dec. 13 /PRNewswire-FirstCall/ -- BioMed Realty Trust, Inc.
(NYSE: BMR) today announced that, in connection with the recently completed
offering of $175.0 million aggregate principal amount of 4.50% Exchangeable
Senior Notes Due 2026 (inclusive of a $25.0 million
over-allotment option) by its operating partnership, BioMed Realty, L.P.,
BioMed Realty Trust intends to file with the Securities and Exchange
Commission, on or around January 5, 2007, a resale registration statement on
Form S-3 to cover the resales of BioMed Realty Trust common stock that may be
issued from time to time upon exchange or redemption of the notes. The resale
registration statement is anticipated to be immediately effective upon filing.
Holders of the notes who wish to be named in the prospectus to be
contained in the resale registration statement in order to sell the common
stock issuable to them upon exchange or redemption of their notes should
complete a selling stockholder notice and questionnaire contained in the
offering memorandum for the notes and return it, no later than December 20,
2006, to: BioMed Realty Trust, Inc., 17140 Bernardo Center Drive, Suite 222,
San Diego, CA 92128, Attention: General Counsel.
This release is being issued in order to comply with the terms of the
indenture and registration rights agreement relating to the notes. This
release shall not constitute an offer to sell or the solicitation of an offer
to buy any of BioMed Realty Trust's or its operating partnership's securities,
nor shall it constitute an offer, solicitation or sale in any jurisdiction in
which such offer, solicitation or sale is unlawful.
Safe Harbor Statement
This press release contains forward-looking statements within the meaning
of the Private Securities Litigation Reform Act of 1995 based on current
expectations, forecasts and assumptions that involve risks and uncertainties
that could cause actual outcomes and results to differ materially. These
risks and uncertainties include, without limitation: general risks affecting
the real estate industry (including, without limitation, the inability to
enter into or renew leases, dependence on tenants' financial condition, and
competition from other developers, owners and operators of real estate);
adverse economic or real estate developments in the life science industry or
the company's target markets; risks associated with the availability and terms
of financing and the use of debt to fund acquisitions and developments;
failure to manage effectively the company's growth and expansion into new
markets, or to complete or integrate acquisitions successfully; risks and
uncertainties affecting property development and construction; risks
associated with downturns in the national and local economies, increases in
interest rates, and volatility in the securities markets; potential liability
for uninsured losses and environmental contamination; risks associated with
the company's potential failure to qualify as a REIT under the Internal
Revenue Code of 1986, as amended, and possible adverse changes in tax and
environmental laws; and risks associated with the company's dependence on key
personnel whose continued service is not guaranteed. For a further list and
description of such risks and uncertainties, see the reports filed by the
company with the Securities and Exchange Commission, including the company's
most recent annual report on Form 10-K and quarterly reports on Form 10-Q.
The company disclaims any intention or obligation to update or revise any
forward-looking statements, whether as a result of new information, future
events or otherwise.
SOURCE BioMed Realty Trust, Inc.
/CONTACT: Kent Griffin, Chief Financial Officer of BioMed Realty Trust,
CO: BioMed Realty Trust, Inc.
IN: HEA MTC RLT CST
-- LAW095 --
5815 12/13/2006 21:31 EST http://www.prnewswire.com